Data Article

Data on the association between CTRP1 and future major adverse cardiovascular events in patients undergoing coronary angiography

Axel Muendlein a, Andreas Leiherer a, b, c, Christoph Saely a, c, d, e, Janine Ebner a, b, Kathrin Geiger a, Eva Maria Brandtner a, Alexander Vonbank a, d, Peter Fraunberger b, Heinz Drexel a, c, e, f, *

a Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria
b Medical Central Laboratories, Feldkirch, Austria
c Private University of the Principality of Liechtenstein, Triessen, Liechtenstein
d Department of Medicine and Cardiology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria
e Division of Angiology, Swiss Cardiovascular Center, University Hospital of Bern, Bern, Switzerland
f Drexel University College of Medicine, Philadelphia, PA, USA

A R T I C L E   I N F O

Article history:
Received 24 April 2019
Received in revised form 17 May 2019
Accepted 28 May 2019
Available online 7 June 2019

Keywords:
Major adverse cardiovascular events
CTRP1
Risk factor
Adipokine
Prospective study

A B S T R A C T

This article provides additional data on the association of the new adipokine CTRP1 with the incidence of future major adverse cardiovascular events in a prospective cohort of patients undergoing coronary angiography. In this regard, multivariable Cox proportional hazards models taking into account cardiac risk markers are presented. Additionally, data on the impact of baseline variables including metabolic traits and co-morbidities on the incidence of future major adverse cardiovascular events are shown. This data article is associated to the research article titled ‘The Novel Adipokine CTRP1 is Significantly Associated with the Incidence of Major Adverse Cardiovascular Events’ Muendlein et al., 2019.

© 2019 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
1. Data

A significant association between CTRP1 and major adverse cardiovascular events (MACE) in patients undergoing coronary angiography has been reported in the associated research article [1]. In addition to the baseline characteristics of the selected study population given in the main article, Table 1 of this article shows the impact of most baseline variables on the incidence of MACE. Table 2 shows further data regarding multivariable Cox proportional hazards models adjusting for age, sex, body mass index, type 2 diabetes mellitus, significant coronary artery disease, hypertension, smoking, LDL cholesterol, HDL cholesterol, and estimated glomerular filtration rate and additionally for the extent of coronary artery disease as well as the percentage of left ventricular ejection fraction (model a) or inflammatory markers including fibrinogen and C-reactive protein (model b).

2. Experimental design, materials and methods

The present dataset included 539 consecutive Caucasian patients, who were referred to elective coronary angiography for the evaluation of established or suspected stable CAD at the academic teaching hospital Feldkirch, Austria. Baseline characteristics were obtained as described in the associated main article [1] and in previous reports [2,3]. In short, the extent of atherosclerosis was defined as the number of ≥50% lesions. Left ventricular function was assessed by 2D echocardiography. Venous blood samples were collected after an overnight fast of 12 h prior to angiography and laboratory measurements were performed from fresh serum or plasma samples or from serum or plasma samples.
C-reactive protein (CRP) was measured by particle enhanced immunological agglutination (Roche, Switzerland) on a Hitachi Cobas 501. Serum CTRP1 levels were determined using a commercial enzyme-linked immunosorbent assay (ELISA) kit (Biovendor, Brno, Czech Republic; article number: RD191153100R).

During a mean follow-up period of 5.9 ± 2.2 years (with a total of 8 years) cardiovascular events were recorded. Out of the 539 patients initially included in the present study, 15 subjects were lost to follow-up. MACE was defined as a three-point composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. Time and causes of death were regularly obtained from a national survey (Statistik Austria, Vienna, Austria) or from hospital records.

Hazard ratios (HRs) and 95% confidence intervals of the HRs were derived from univariable and multivariable Cox proportional hazards models; log-transformed continuous variables were z-

| Table 1 |
|---------------------------------|
| Impact of baseline variables on the incidence of major adverse cardiovascular events. |
| | HR (95%CI) | p-value |
|---|---|---|
| Age (years) | 1.20 [0.96–1.49] | 0.116 |
| Male gender | 0.99 [0.68–1.43] | 0.945 |
| BMI (kg/m²) | 0.86 [0.72–1.04] | 0.862 |
| Metabolic syndrome | 1.33 [0.94–1.88] | 0.111 |
| Type 2 diabetes mellitus | 1.76 [1.23–2.50] | 0.002 |
| Hypertension | 1.12 [0.72–1.77] | 0.613 |
| Smoking | 1.21 [0.84–1.74] | 0.302 |
| LDL-Cholesterol (mg/dl) | 0.84 [0.71–1.00] | 0.049 |
| HDL-Cholesterol (mg/dl) | 0.74 [0.62–0.90] | 0.002 |
| Triglycerides (mg/dl) | 1.06 [0.88–1.26] | 0.550 |
| eGFR (ml/min/1.73m²) | 0.70 [0.58–0.85] | <0.001 |
| Significant CAD | 1.14 [0.79–1.65] | 0.482 |
| Extent of CAD | 1.65 [1.12–2.44] | 0.012 |
| LDV (%) | 1.15 [1.05–1.26] | 0.002 |
| C-reactive protein (mg/dl) | 0.61 [0.51–0.73] | <0.001 |
| Fibrinogen (mg/dl) | 1.14 [1.01–1.47] | 0.036 |
| BNP (pg/dl) | 1.51 [1.31–1.75] | <0.001 |

Results of univariate Cox regression analysis. Age, BMI, LDL-C, HDL-C, triglycerides, eGFR, LVEF, C-reactive protein, fibrinogen, and BNP were log-transformed and z-transformed before analysis. Coronary artery stenoses with stenotic narrowing ≥50% were defined as significant CAD. The extent of CAD was defined as the number of ≥50% lesions. BMI, body mass index; eGFR, estimated glomerular filtration rate; NAFLD, non-alcoholic fatty liver disease; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; BNP, brain natriuretic peptide; HR, hazard ratio; CI, confidence interval.

| Table 2 |
|---------------------------------|
| Adjusted associations between CTRP1 quartiles and the incidence of major adverse cardiovascular events - results from multivariable Cox regression analyses. |
| CTRP1 quartiles | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | p trend-value |
|---|---|---|---|---|---|
| Adjusteda hazard ratio | 1reference 1.98 [1.12–3.50]; p = 0.019 | 2.18 [1.23–3.77]; p = 0.005 | 1.86 [1.06–3.27]; p = 0.030 | 0.036 |
| Adjustedb hazard ratio | 1reference 1.83 [1.04–3.23]; p = 0.037 | 2.16 [1.25–3.75]; p = 0.006 | 1.80 [1.03–3.15]; p = 0.038 | 0.041 |

Adjustment model a adjusts for age, sex, BMI, type 2 diabetes mellitus (T2DM), angiographically significant coronary artery disease (CAD), the extent of CAD, percentage of left ventricular ejection fraction (LVEF), hypertension, smoking, LDL cholesterol, HDL cholesterol, and estimated glomerular filtration rate (eGFR); model b adjusts for age, sex, BMI, type 2 diabetes mellitus (T2DM), angiographically significant coronary artery disease (CAD), hypertension, smoking, LDL cholesterol, HDL cholesterol, estimated glomerular filtration rate, (eGFR), fibrinogen, and C-reactive protein (CRP). Age, BMI, LVEF, LDL cholesterol, HDL cholesterol, eGFR, fibrinogen, and CRP were log-transformed before included in multivariable Cox regression analyses.

stored at –80 °C. C-reactive protein (CRP) was measured by particle enhanced immunological agglutination (Roche, Switzerland) on a Hitachi Cobas 501. Serum CTRP1 levels were determined using a commercial enzyme-linked immunosorbent assay (ELISA) kit (Biovendor, Brno, Czech Republic; article number: RD191153100R).

During a mean follow-up period of 5.9 ± 2.2 years (with a total of 8 years) cardiovascular events were recorded. Out of the 539 patients initially included in the present study, 15 subjects were lost to follow-up. MACE was defined as a three-point composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. Time and causes of death were regularly obtained from a national survey (Statistik Austria, Vienna, Austria) or from hospital records.

Hazard ratios (HRs) and 95% confidence intervals of the HRs were derived from univariable and multivariable Cox proportional hazards models; log-transformed continuous variables were z-
transformed for these analyses. P-values <0.05 were considered significant. Statistical analyses were performed with SPSS 25.0 for Windows (IBM, Armonk, New York, USA).

The present study has been approved by the Ethics Committee of the University of Innsbruck, Austria, and written informed consent was given by all participants.

Acknowledgements

We are grateful to the Vorarlberger Landesregierung (Bregenz, Austria) for continuously supporting our research institute.

Conflict of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] A. Muendlein, A. Leiherer, C.H. Saely, J. Ebner, K. Geiger, E.M. Brandtner, A. Vonbank, P. Fraunberger, H. Drexel, The Novel adipokine CTRP1 is significantly associated with the incidence of major adverse cardiovascular events, Atherosclerosis 286 (2019), https://doi.org/10.1016/j.atherosclerosis.2019.04.222.
[2] A. Muendlein, C.H. Saely, A. Leiherer, P. Fraunberger, E. Kinz, P. Rein, A. Vonbank, D. Zanolin, C. Malin, H. Drexel, Angiopoietin-like protein 4 significantly predicts future cardiovascular events in coronary patients, Atherosclerosis 237 (2014), https://doi.org/10.1016/j.atherosclerosis.2014.10.028.
[3] A. Leiherer, A. Muendlein, C.H. Saely, J. Ebner, E.M. Brandtner, P. Fraunberger, H. Drexel, Serum uromodulin is a predictive biomarker for cardiovascular events and overall mortality in coronary patients, Int. J. Cardiol. 231 (2017), https://doi.org/10.1016/j.ijcard.2016.12.183.